The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 June 2026•

1 min read

AbbVie Stock Hits All-Time High at $245.26 on Acquisition, Dividend Boost

Key Facts

1AbbVie stock reached an all-time high of $245.26.

2AbbVie acquired Apogee Therapeutics for approximately $10.9 billion.

3AbbVie's board declared a quarterly cash dividend of $1.73 per share.

In a move reflecting growing confidence in the pharmaceutical sector, AbbVie stock hit an all-time high of $245.26, according to reports. The surge was supported by the company's announcement of the acquisition of Apogee Therapeutics for approximately $10.9 billion, alongside the board's declaration of a quarterly cash dividend of $1.73 per share.

The stock has posted strong gains year-to-date, driven by the strength of its pipeline in immunology and oncology, as well as the acquisition deal which bolsters its respiratory therapies portfolio. The closing price on June 25 stood at $243.14, compared to a session high of $244.61 and a low of $233.66, per market data.

Investors are watching for pipeline updates and potential regulatory approvals, which could serve as additional catalysts. At current levels, the stock trades just below its all-time high, leaving it susceptible to profit-taking should no fresh catalysts emerge to support further upside.